This is the authors' abstract. We don't add key points for this paper.
Background Post-bronchodilator (BD) spirometry is underused in primary care settings, limiting COPD diagnosis. This study aimed to derive and validate pre-BD thresholds that safely rule in COPD and enable immediate diagnosis. Methods We derived pre-BD FEV1/FVC thresholds using a nationally representative derivation dataset (CPHS, n=6360 with pre-BD ratio <0.7), with cross-sectional external validation in the China Kadoorie Biobank (CKB, n=1890) and longitudinal validation in a national screening cohort (NSC, n=7620 with 1-year follow-up). The optimal threshold was selected based on positive predictive value (PPV) for post-BD FEV1/FVC <0.7. One-year longitudinal follow-up assessed diagnostic stability and prognostic value. Findings A pre-BD threshold of 0.56 was identified, yielding a PPV of 0.953 (95% CI, 0.939–0.965) in derivation set and 0.919 (95% CI, 0.875–0.940) in the CKB validation set. In subgroups with higher prior probability (male, age >60 years, smoking, and with respiratory symptoms), the PPV was further increased. At one-year follow-up in the NSC, 86.9% of participants with baseline pre-BD <0.56 still met the post-BD COPD criteria. Patients below 0.56 had significantly higher risks of acute exacerbation (OR, 3.34; 95% CI, 2.55–4.37) and respiratory hospitalization (OR, 3.42; 95% CI, 2.65–4.42). An alternative threshold of 0.62 gave a PPV of 0.891 (95% CI, 0.866–0.913) in CKB and allowed 33.8%–49.0% of participants across cohorts to bypass post-BD testing. Interpretation A pre-BD FEV1/FVC threshold of 0.56 effectively "rules-in" COPD in primary care and identifies patients with poor prognosis. The alternative threshold of 0.62 offers a practical option to further reduce post-BD testing while maintaining an acceptable PPV. Both thresholds facilitate pragmatic triage and early diagnosis without routine post-BD testing. Funding This work was funded by National High Level Hospital Clinical Research Funding (2025-NHLHCRF-JBGS-B-WZ-18), Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0506003, 2023ZD0506306, 2023ZD0510101, 2023ZD0510100), Social Development Project of Yunnan Province (202403AC100006) and Beijing Nova Program (20250484849).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: